By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Tricyclic antidepressant > Imipramine

Imipramine

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|625 words

What is Imipramine?

Imipramine is a tricyclic antidepressant (TCA) medication that has been used since the 1950s to treat depression and other psychiatric conditions. Originally developed as one of the first effective antidepressants, it belongs to a class of medications that work by affecting neurotransmitter levels in the brain. While newer antidepressants have largely replaced tricyclics as first-line treatments, imipramine remains an important therapeutic option for certain conditions.

Uses

Imipramine is prescribed for several medical conditions:

  • Major depressive disorder: The primary indication, particularly for severe depression that hasn’t responded to other treatments
  • Childhood enuresis (bedwetting): One of the few medications approved for treating persistent bedwetting in children over age 6
  • Panic disorder: Used to reduce the frequency and severity of panic attacks
  • Chronic pain conditions: Off-label use for neuropathic pain, fibromyalgia, and other chronic pain syndromes
  • Attention deficit hyperactivity disorder (ADHD): Sometimes prescribed when stimulant medications are not suitable or effective

How it works

Imipramine blocks the reuptake of two important neurotransmitters in the brain: norepinephrine and serotonin. By preventing these chemicals from being quickly removed from nerve synapses, the medication increases their availability and activity in brain circuits involved in mood regulation. This mechanism also affects other neurotransmitter systems, which explains both its therapeutic effects and its side effect profile.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Dry mouth
  • Constipation
  • Drowsiness or sedation
  • Dizziness, especially when standing up
  • Blurred vision
  • Weight gain
  • Difficulty urinating
  • Increased sweating

Serious side effects that require immediate medical attention:

  • Irregular heartbeat or chest pain
  • Severe confusion or hallucinations
  • Seizures
  • Severe allergic reactions
  • Suicidal thoughts, especially in young adults

Warnings and precautions

  • Suicide risk: All antidepressants carry an FDA black box warning for increased suicide risk in children, adolescents, and young adults under 25, particularly during the first few weeks of treatment
  • Heart conditions: Should be used with extreme caution in patients with heart disease, as tricyclics can affect heart rhythm and blood pressure
  • Pregnancy and breastfeeding: Classified as pregnancy category D; potential risks to the fetus must be weighed against benefits, and the drug passes into breast milk
  • Elderly patients: Increased sensitivity to side effects, particularly confusion, falls due to dizziness, and heart problems
  • Liver and kidney disease: Dosage adjustments may be necessary as these organs are responsible for processing and eliminating the medication

Interactions

Imipramine has numerous significant drug interactions:

  • Monoamine oxidase inhibitors (MAOIs): Can cause dangerous, potentially fatal reactions and should be separated by at least 14 days
  • SSRIs and SNRIs: May increase imipramine levels and risk of serotonin syndrome
  • Blood thinners (warfarin): Imipramine may increase bleeding risk by affecting warfarin metabolism
  • Heart rhythm medications: Combined effects on heart electrical activity can be dangerous
  • Seizure medications: May lower seizure threshold and affect the effectiveness of anticonvulsants
  • Sedatives and alcohol: Increased drowsiness and impaired coordination
  • Thyroid medications: May increase effects and side effects of both medications
  • St. John’s wort: Can reduce imipramine effectiveness and increase side effects

Check interactions with the GMJ Interaction Checker

Dosage

Imipramine dosing varies significantly based on the condition being treated and individual patient factors. For depression in adults, treatment typically starts with 75-100 mg daily, divided into multiple doses or taken as a single bedtime dose. The dose may be gradually increased to 200-300 mg daily as needed. For childhood enuresis, doses are much lower, typically starting at 25 mg before bedtime. Elderly patients usually require lower starting doses due to increased sensitivity. Dosage adjustments should always be made gradually under medical supervision, and all dosing decisions should be determined by a qualified healthcare provider based on individual patient needs and response.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Imipramine." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/imipramine/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Why Women Choose Freebirth: What Research Reveals About Unattended Childbirth

A growing number of women are choosing unattended childbirth, driven by desire…

The Optimal Height for Elite Soccer Players: What Sports Science Reveals

Elite soccer demonstrates position-specific height selection rather than universal stature advantage. Analysis…

International Survey Reveals Critical Gaps in Cardio-Oncology Training Despite Rising Clinical Demand

An international survey presented at ESC Cardio-Oncology 2026 has identified substantial deficiencies…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Amitriptyline

By
Prof. Giorgi Pkhakadze
02/06/2026

Nortriptyline

By
Prof. Giorgi Pkhakadze
02/06/2026

Clomipramine

By
Prof. Giorgi Pkhakadze
02/06/2026

Desipramine

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up